A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Eligibility Criteria

• 1. Male or female, age 18 \~ 75 (include both ends, or other age range required by local regulations or IRB).
• 2. Escalation Part: Patients must have histological or cytological confirmed advanced solid tumors that have progressed on or intolerant to standard therapy or whom no standard therapy exists; and patients with advanced HCC must satisfy:
• 1. BCLC stage B or C and Child-Pugh score 5\~6
• 2. Patient must provide archived tissue sample or biopsy for FGF19 overexpression central lab testing
• 1. Patient must provide archived tissue sample or biopsy for FGF19 overexpression central lab testing, and the result must be positive
• 2. Patient must have at least 1 measurable lesion (RECIST V1.1)
• 3. Child-Pugh score 5\~7 without hepatic encephalopathy, no clinically apparent ascites or require medical intervention
• 3. ECOG performance status 0\~1
• 4. Life expectancy ≥ 3 months
• 5. Adequate organ function and bone marrow function as indicated by the following screening assessments performed within 14 days prior to the first dose of study drug (without blood transfusion or medication with stimulation factors within 14 days before 1st dose):
• 1. Absolute neutrophil count (ANC) ≥1.5×109/L
• 2. Platelet count (PLT) ≥75×109/L
• 3. Hemoglobin (Hb) ≥80 g/L
• 4. Total bilirubin (TBIL) ≤1.5×ULN
• 5. Aspartate transaminase (AST) and alanine transaminase (ALT), ≤3×ULN (for patient with liver metastasis in escalation part or patient in expansion part: AST and AST ≤5×ULN)
• 6. Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (Crcl) ≥50 mL/min based on Cockcroft-Gault formula
• 6. Patients with HBV infection should follow local clinical practice and anti-HBV therapy should be performed to ensure adequate viral suppression (HBV-DNA \< 10000 IU/mL or equivalent copies/mL prior to enrollment). Patients are examined every cycle to monitor HBV-DNA levels. If virus reactivation occurred for patients without anti-viral treatment when enrolled, anti-HBV therapy will be started following local practice.
• 7. Non-surgically sterilized male or female patients of childbearing potential must agree to use effective methods of birth control during the study and for up to 6 months after the last dose of study drug. Non-surgically sterilized female patients of childbearing potential must in non-lactation period, and have a negative β-HCG test result within 7 days before first administration.
• 8. Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
• 1. Known allergy or hypersensitivity to any component of the investigational drug product.
• 2. Previous treatment with FGFR4 or pan-FGFR pathway inhibitors (pan-FGFR inhibitors should be confirmed with the sponsor).
• 3. Has a known second primary malignancy required active treatment.
• 4. Has a known active central nervous system (CNS) metastases (if stable disease after treatment, free from or daily dexamethasone \<10 mg or other equivalent glucocorticoids can be enrolled).
• 5. Liver tumor volume accounts for ≥50% of the whole liver.
• 6. Inability to take oral medication or other factors significant preclude adequate absorption of oral medication, such as previously received total gastrectomy, residual gastric dysfunction after subtotal gastrectomy, short bowel syndrome after small bowel resection, active diarrhea required drug treatment, etc.
• 7. Severe irritable bowel syndrome requires drug therapy.
• 8. Prior organ transplantation requires anti-rejection drug therapy.
• 9. Previous anti-cancer therapy prior to initiation of study treatment: major surgery (except palliative therapy), radiotherapy (bone-marrow exposure \>30%), routine chemotherapy \<4 weeks (chemotherapy with nitrosourea or mitomycin \<6 weeks); oral chemotherapy, endocrine therapy, molecular targeted therapy or immunotherapy within ≤ 5 half-life or ≤ 4 weeks (whichever is shorter).
• 10. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade ≤1 severity (CTCAE v5.0) with the exception of which inclusion criteria allowed, alopecia, vitiligo and neurotoxicity Grade ≤2 that investigator believe don't affect safety assessment.
• 11. Concomitant use of strong inhibitors or inducers of CYP3A4 (include grapefruit juice, grapefruit hybrids, pomegranates, starfruit, pomelos, Seville oranges or juice or products) within at least 14 day prior to the first dose of the study drug.
• 12. Impaired cardiac function or clinically significant cardiac disease, including any one of the following:
• 1. New York Heart Association class III or IV congestive heart failure, unstable angina, or myocardial infarction within 6 months before administration of the study drug;
• 2. Clinically significant cardiac arrhythmia requiring active therapy;
• 3. Uncontrolled hypertension;
• 4. Left ventricle ejection fraction\<50%
• 5. Prolongation of QTcF (average of three times of examine, male \> 450 ms, female \> 470 ms) (Note: QTc interval corrected by Frederica's formula) at screening, and other ECG abnormalities with clinical significant by the judge of the investigator.
• 13. Active infection or unexplained fever \> 38.5℃.
• 14. Active or record of gastrointestinal bleeding within 6 months (e.g. esophageal varices or ulcer bleeding).
• 15. Patients with active HCV infection (HCV-RNA\>103 copies/mL or following local clinical practice) and require concomitant anti-HCV therapy during the study; or HBV HCV co-infection.
• 16. History of immunodeficiency, including HIV serum test positive, or other acquired/congenital immunodeficiency disease, or active tuberculosis.
• 17. Any other clinically significant comorbidities, such as respiratory, metabolic, congenital, endocrine or central nervous system disease, or any other medical conditions, mental disturbances or social determinants, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.
• 18. Combined with portal vein tumor thrombus of type IV.